Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma

Cancer

Volumn 107, Issue 9, 2006, Pages 2212-2222

  Lu, Sheng Nan ^a,b   Wang, Jing Houng ^a,b   Liu, Shiann Long ^c   Hung, Chao Hung ^a,b   Chen, Chien Hung ^a,b   Tung, Hung Da ^a,d   Chen, Tsung Ming ^a,e   Huang, Wu Shiung ^a,f   Lee, Chuan Mo ^a,b   Chen, Chia Cheng ^g   Changchien, Chi Sin ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c Min Sheng Clinic at Lieujia Township   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^f E DA HOSPITAL   (Taiwan)

^g Tainan and Health Center of Gaoshu Township   (Taiwan)

Author keywords

fetoprotein; Cirrhosis; Community screening; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Platelet; Ultrasonography

Indexed keywords

ALPHA FETOPROTEIN; VIRUS ANTIBODY;

ADULT; AGED; ARTICLE; CANCER SCREENING; CHRONIC HEPATITIS; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ECHOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; AREA UNDER CURVE; BLOOD PLATELETS; CARCINOMA, HEPATOCELLULAR; COMMUNITY HEALTH SERVICES; COMORBIDITY; FEMALE; FIBROSIS; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TAIWAN; THROMBOCYTOPENIA;

EID: 33750507912     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22242     Document Type: Article

References (41)

1. Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98:257-261.
2. Chuang WL, Chang WY, Lu SN, et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer. 1992;69:2052-2054.
3. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol. 1994;17:71-91.
4. Omata M, Tateishi R, Yoshida H, et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology. 2004;127:S159-S166.
5. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology. 1986;90:263-267.
6. Caturelli E, Bartolucci F, Biasini E, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol. 2002;97:397-405.
7. Tang ZY. Screening and early treatment of primary liver cancer-with special reference to the east part of China. Ann Acad Med Singapore. 1980;9:234-239.
8. Wu JC, Lee SD, Hsiao BCJ, et al. Mass screening of primary hepatocellular carcinoma by alpha-fetoprotein in a rural area of Taiwan - a dried blood spot method. Liver. 1988;8:100-104.
9. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842-846.
10. Chen CJ, Lu SN, You SL, et al. Community-based hepatocellular carcinoma screening in seven townships in Taiwan. J Formas Med Assoc. 1995;94:s94-s102.
11. Mima S, Sekiya C, Kanagawa H, et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol. 1994;9:361-365.
12. Zhan BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
13. Daniele B, Bencivenga A, Megna AS, et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127:S108-S112.
14. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168-174.
15. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B DNA level. JAMA. 2006;295:65-73.
16. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:835-850.
17. Ono E, Shiratori Y, Okudaira T, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res. 1999;15:192-200.
18. Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002;36:S57-S64.
19. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376-1382.
20. Lu SN, Wang JH, Kuo YK, et al. Predicting the prevalence of antibody to hepatitis C virus (HCV) in a community by the prevalence of elevated levels of alanine aminotransferase: a method to identify areas endemic for HCV. Am J Trop Med Hyg. 2002;67:145-150.
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
22. Hung CH, Lu SN, Wang JH, et al. Correlation of ultrasonographic and pathologic diagnoses for hepatitis B and C related liver cirrhosis. J Gastroenterol. 2003;38:153-157.
23. Hanly JA, McNeil BJ. The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
24. Hanly JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;184:839-843.
25. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation on liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.
26. Mardini H, Record C. Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy? Ann Clin Biochem. 2005;42:441-447.
27. Patel K, Lajoie A, Heaton S, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol. 2003;18:253-257.
28. Braden B, Faust D, Sarrazin U, et al. 13C-metacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2005;21:179-185.
29. George JN. Platelets. Lancet. 2000;355:1531-1539.
30. Rios R, Sangro B, Herrero I, et al. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol. 2005;100:1311-1316.
31. Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol. 2002; 37:572-577.
32. Moriyama M, Matsumura H, Aoki H, et al. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. Intervirology. 2003;46:296-307.
33. Miyazawa K, Moriyama M, Mikuni M, et al. Analysis of background factors and evaluation of a population at high risk of hepatocellular carcinoma. Intervirology. 2003;46:150-156.
34. Ryu T, Nishimura S, Miura H, et al. Thrombopoietin-producing hepatocellular carcinoma. Intern Med. 2003;42:730-734.
35. Wang CS, Yao WJ, Wang ST, et al. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis. 2004;39:790-796.
36. Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country-geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol. In press.
37. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
38. Kaneko K, Shirai Y, Wakai T, et al. Low preoperative platelet counts predict a high mortality after partial hepatectomy in patients with hepatocellular carcinoma. World J Gastroenterol. 2005;11:5888-5892.
39. Gamma C, Di Marco V, Orlando A, et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol. 2005;42:535-540.
40. Pompili M, Rapaccini GL, Covino M, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer. 2001;92:126-135.
41. Reichman TW, Bahramipour P, Barone A, et al. Hepatitis status, Child-Pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg. 2005;9:638-645.